Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;107(11):2720-2724.
doi: 10.3324/haematol.2022.281053.

Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation

Nathalie Forgeard  1 , Marine Baron  1 , Jonathan Caron  2 , Clementine Boccon-Gibod  1 , Daphne Krzisch  1 , Nayara Guedes  1 , Veronique Morel  1 , Nathalie Jacque  1 , Maya Ouzegdouh  1 , Sylvain Choquet  1 , Clotilde Bravetti  2 , Florence Nguyen-Khac  3 , Elise Chapiro  3 , Veronique Leblond  1 , Damien Roos-Weil  4
Affiliations

Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation

Nathalie Forgeard et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Description of inflammatory patients. (A) C-reactive protein (CRP) distribution (density plot), (B) proportion of 6q deletion (del6q) patients according to CRP levels, (C) correlation between CRP and hematological response.
Figure 2.
Figure 2.
Outcomes according to inflammatory and non-inflammatory subgroups. (A) Treatment-free survival, (B) progression-free survival and (C) overall survival according to inflammatory (pink) and non-inflammatory (blue) subgroups. Survival comparisons were performed using log-rank test and shown with Kaplan-Meier curves. All P values were 2-sided, with P<0.05 indicating statistical significance. Statistical analyses were performed with R 3.6.3 (Foundation for Statistical Computing, Vienna, Austria).
See this image and copyright information in PMC

References

    1. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R. Molecular pathogenesis of Waldenström’s macroglobulinemia. Haematologica. 2012;97(9):1281-1290. - PMC - PubMed
    1. Hunter ZR, Xu L, Yang G, et al. . The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646. - PubMed
    1. Nguyen-Khac F, Lambert J, Chapiro E, et al. . Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 2013;98(4):649-654. - PMC - PubMed
    1. Krzisch D, Guedes N, Boccon-Gibod C, et al. . Cytogenetic and molecular abnormalities in Waldenström’s macroglobulinemia patients: correlations and prognostic impact. Am J Hematol. 2021;96(12):1569-1579. - PubMed
    1. Pophali PA, Bartley A, Kapoor P, et al. . Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014-1017. - PubMed

Publication types